海南赞邦制药有限公司

Zambon S.p.A, a global leader in pharmaceuticals and chemicals, was founded in Vicenza, Italy in 1906. Through a century of growth marked by continuous innovation, adaptable business strategies, and customer-centric values, the company has ascended to the ranks of the world's premier pharmaceutical firms. Today, Zambon operates across 16 nations, holding a dominant position in respiratory system antioxidant therapy and urinary system antimicrobial treatments.

In 1998, Zambon established Hainan Zambon Pharmaceutical Co., Ltd in China. Over the last two decades, this subsidiary has made significant strides. By 2000, it had secured national GMP certification and implemented an advanced fully automated granulation process. Leveraging the robust R&D capabilities of its parent company, Hainan Zambon's product portfolio encompasses treatments for respiratory conditions, urinary issues, endocrine disorders, and cardiovascular ailments. In 2007, it underwent a rigorous inspection by AIFA, Italy's regulatory body, and earned EU GMP certification, making it the first pharmaceutical firm in Hainan to achieve this distinction.

As Zambon looks ahead, it intends to uphold its legacy of excellence in medical research and global expansion, striving to enhance human well-being worldwide. Meanwhile, Hainan Zambon plans to harness the strengths of its parent corporation to introduce cutting-edge products to China, offering unparalleled services that contribute to healthier living experiences.